| News

BaseLaunch supports Switzerland as an innovation location

27.08.2019

Switzerland often receives awards for its innovative strength. Life sciences have generally played a huge part in this acclaim. The BaseLaunch accelerator operated by BaselArea.swiss is a major reason for innovation, a media report has found.

BaseLaunch

In its latest issue, the digital magazine “Pharma – Technology Focus” has dedicated an article to innovation in Switzerland. It explores the journey from startup to listed company and presents some of the success stories in the life sciences sector. The BaseLaunch accelerator operated by the innovation and economic promotion agency BaselArea.swiss is playing a key role in this development.

Almost two thirds of those in employed in the Swiss pharmaceutical sector work in the greater Basel area: 700 companies, more than 30,000 employees and R&D investment of 21 billion Swiss francs – these impressive figures are cited in the article. Industry activity is just one element of life sciences in Basel. The second is academic research, as director of BaseLaunch Stephan Emmerth explains, adding that more than 1,000 research groups and 13 research institutes are based in the region. Basel is therefore the perfect place for startups – and that’s where BaseLaunch comes into play.

The accelerator was founded in 2017 and is supported by the pharma giants Roche and Novartis. BaseLaunch helps startups launch and further develop their business models. This makes them attractive for venture capital funds and major pharma corporations, which invest as a result. “To do so, we offer grants of up to 250,000 francs and access to our partners,” said Stephan Emmerth. BaseLaunch has supported ten startups in this way to date, embedding them in the Basel area’s life sciences ecosystem.

In future, these companies could quite likely appear on the SIX Swiss Exchange. According to the magazine, SIX is the most important biotech exchange in Europe. The first major company from Basel to list on the exchange was Lonza in 1999 and Actelion a year later. After Johnson & Johnson took over Actelion, the spin-off Idorsia also decided to go public. They are considered pioneers, and the next company that follows in their footsteps could quite possibly have been helped on its way by BaseLaunch.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

Basel Area Business & Innovation, Innovation

docdok.health involved in coronavirus research project

A research project is investigating the improvement in the condition of patients who have been hospitalized due to COVID-19. docdok.health based in Basel is contributing the smartphone app for the project.

Read More
Basel Area Business & Innovation, Innovation

Celonic agrees cooperation to combat coronavirus

The Basel-based biopharmaceutical company Celonic Group has agreed a partnership with Airway Therapeutics from the USA. Together, the two companies are planning to develop a drug to treat coronavirus.

Read More
Basel Area Business & Innovation, Innovation, Invest

Idorsia receives payment of 45 million US dollars

The Allschwil-based pharmaceutical company Idorsia receives a payment of 45 million US dollars as part of an agreement with Neurocrine Biosciences and shall also be entitled to claim milestone payments in future. Neurocrine has exercised a licensing option for a drug developed by Idorsia to treat epilepsy..

Read More
Basel Area Business & Innovation, Innovation

Humard robot disinfects using UV light

Humard has developed a robot that can disinfect spaces using UV light. For this, the system manufacturer from the canton of Jura has adapted a mobile industrial robot that is otherwise used in warehouse logistics.

Read More
Basel Area Business & Innovation, Innovation, Invest

Roche authorized to distribute coronavirus antibody tests

Roche has received Emergency Use Authorization in the USA for an antibody test in connection with the novel coronavirus. The tests are already being distributed around the world. In May, production capacities are to already be scaled up to the high double-digit million area.

Read More
Basel Area Business & Innovation, Invest

Basel is the most popular Swiss location for headquarters

Basel is valued as a location for company headquarters. In a rating from the fDi Intelligence platform of the Financial Times, Basel achieves eighth place in Europe. No other Swiss city does better.

Read More
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Healthtech sector growing rapidly in the Basel Area

The investment and innovation promotion agency Basel Area Business & Innovation, previously known as BaselArea.swiss, can look back on a successful year in 2019. In this regard, positive developments in the healthtech sector and in Switzerland Innovation Park Basel Area stand out.

Read More
Basel Area Business & Innovation, Innovation, Invest

Support program has roots in Basel

The online program Selfapy supports people suffering from mental health conditions during the coronavirus lockdown. BaselArea.swiss has provided startup help by way of its DayOne initiative.

Read More
Basel Area Business & Innovation, Innovation

University Hospital Basel treats coronavirus patients with plasma

The University Hospital Basel is the first Swiss hospital to have treated two Covid-19 patients with the plasma from a patient who has recovered from the virus, which means that they are receiving the appropriate antibodies. This method is a potential therapeutic option.

Read More
Basel Area Business & Innovation, Innovation

Botnar Research Center advancing research into coronavirus

The Basel-based Botnar Research Center for Child Health is providing capital in the amount of 15 million Swiss francs to its four partner institutions. In this way, the University of Basel should be in a position to advance research into dealing with the coronavirus outbreak.

Read More
1 2 3 18

Do you have a question? We'd like to hear from you.